Combining a new drug with an antioxidant for early dementia treatment
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
This study is testing if a new drug combined with an antioxidant can help people with early-stage dementia, like Alzheimer's, think better than just using the drug alone.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 50 Years to 90 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT06467539 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of a combination treatment involving DAOIB, an NMDA-enhancing agent, and an antioxidant in patients with early-stage dementia, specifically Alzheimer's disease and mild cognitive impairment. The study aims to determine if this combined approach can improve cognitive function more effectively than using DAOIB alone. Participants will be assessed based on their cognitive status and will receive either the combination treatment or a placebo. The trial is designed to provide insights into the potential benefits of dual therapy in early dementia.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Alzheimer's disease or mild cognitive impairment who have a Mini-Mental State Examination (MMSE) score between 10 and 26.
Not a fit: Patients with severe comorbid conditions, such as major depressive disorder or significant physical illnesses, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance cognitive function in patients with early dementia, potentially slowing disease progression.
How similar studies have performed: Previous studies have shown some success with NMDA-enhancing agents and antioxidants in dementia treatment, but this specific combination approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of Alzheimer's disease or mild cognitive impairment * MMSE between 10-26 * CDR 1 or 0.5 Exclusion Criteria: * Hachinski Ischemic Score \> 4 * Substance abuse/dependence * Parkinson disease, epilepsy, dementia with psychotic features * Major depressive disorder * Major physical illnesses * Severe visual or hearing impairment
Where this trial is running
Kaohsiung City
- Chang Gung Memorial Hospital — Kaohsiung City, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.